Strategic partnerships Leverage MabVax's collaborative history with prestigious cancer centers ( Memorial Sloan Kettering, Rockefeller University, Sarah Cannon, Honor Health, Imaging Endpoints ) to position co-development or sponsored research opportunities with these or similar institutions, highlighting access to an active clinical program and a robust translational pipeline.

Clinical-stage assets Target biotech and pharma buyers or partners seeking late-stage or near-term opportunities by emphasizing MVT-5873's phase 1 progress, companion diagnostics (MVT-2163), and ongoing radioimmunotherapy program (MVT-1075) as add-on collaborations or licensing prospects.

Specialized radiopharma Position MabVax’s radioimmunotherapy platform as a value-add for radiopharma companies and CROs looking to expand cancer imaging and targeted radionuclide therapy portfolios, highlighting existing early safety signals and target specificity.

Resource-light model Pursue partnerships that optimize capital efficiency given the small internal team (2-10 employees) by proposing out-sourced development, co-development agreements, or milestone-based collaborations with larger pharmas to scale manufacturing and clinical execution.

Strategic exit options Explore acquisition or asset-sale discussions for MabVax’s lead assets and infrastructure, as past history shows a trajectory of asset sale to BioNTech; present a clear value proposition for acquiring either the lead antibody portfolio or the discovery platform to accelerate a partner’s oncology pipeline.